PRINCETON, N.J., Nov. 17,
2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)
(Soligenix or the Company), a late-stage biopharmaceutical company
focused on developing and commercializing products to treat rare
diseases where there is an unmet medical need, announced
today that its 2023 Annual Meeting of Stockholders (the "Annual
Meeting"), which was reconvened on November
16, 2023, has been adjourned for the purpose of soliciting
additional votes with respect to the proposals described in the
Company's definitive proxy statement for the Annual Meeting filed
with the Securities and Exchange Commission (the "SEC") on
August 7, 2023, as supplemented on
September 15, 2023 and September 22, 2023.
The required quorum for the transaction of business at the
Annual Meeting is a majority of the voting power of shares of
common stock issued and outstanding on the record date. There was
less than the required voting power represented in person or by
proxy at the meeting. The Annual Meeting will be reconvened
on December 15, 2023 at 9:00 a.m. Eastern Time and will continue to be
held virtually via live audio-only webcast at
www.virtualshareholdermeeting.com/sngx2023.
The record date for determination of stockholders entitled to
vote at the reconvened Annual Meeting remains the close of business
on July 24, 2023. At the time the
Annual Meeting was adjourned, proxies had been submitted by
stockholders representing approximately 46.46% of the shares of the
Company's common stock issued and outstanding as of the record
date.
Stockholders as of close of business on July 24, 2023, the record date for the Annual
Meeting, are encouraged to vote as soon as possible via the
Internet at www.proxyvote.com or by phone at 1-800-690-6903
(have proxy card available).
Important Information
This material may be deemed to be solicitation material in
respect of the Annual Meeting to be reconvened and held on
December 15, 2023. In connection with
the Annual Meeting, the Company filed a definitive proxy statement
with the SEC on August 7, 2023, and
supplements thereto on September 15,
2023 and September 22, 2023.
BEFORE MAKING ANY VOTING DECISIONS, STOCKHOLDERS ARE URGED TO READ
THE DEFINITIVE PROXY STATEMENT, THE SUPPLEMENTS, AND ANY OTHER
RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN
IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The proxy materials
have been made available to shareholders who are entitled to vote
at the Annual Meeting. The Company's proxy statement and any other
materials filed by the Company with the SEC can be obtained free of
charge at the SEC's website at sec.gov or the Company's
website https://ir.soligenix.com/sec-filings.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing and moving toward
potential commercialization of HyBryte™ (SGX301 or synthetic
hypericin sodium) as a novel photodynamic therapy utilizing safe
visible light for the treatment of cutaneous T-cell lymphoma
(CTCL). With a successful Phase 3 study completed, regulatory
approval is being sought and commercialization activities for this
product candidate are being advanced initially in the U.S.
Development programs in this business segment also include
expansion of synthetic hypericin (SGX302) into psoriasis, our
first-in-class innate defense regulator (IDR) technology,
dusquetide (SGX942) for the treatment of inflammatory diseases,
including oral mucositis in head and neck cancer, and proprietary
formulations of oral beclomethasone 17,21-dipropionate (BDP) for
the prevention/treatment of gastrointestinal (GI) disorders
characterized by severe inflammation including pediatric Crohn's
disease (SGX203).
Our Public Health Solutions business segment includes active
development programs for RiVax®, our ricin toxin vaccine
candidate, as well as our vaccine programs targeting filoviruses
(such as Marburg and Ebola) and CiVax™, our vaccine candidate for
the prevention of COVID-19 (caused by SARS-CoV-2). The development
of our vaccine programs incorporates the use of our proprietary
heat stabilization platform technology, known as
ThermoVax®. To date, this business segment has been
supported with government grant and contract funding from the
National Institute of Allergy and Infectious Diseases (NIAID), the
Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced
Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at https://www.soligenix.com and
follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities, including but
not limited to, potential market sizes, patient populations and
clinical trial enrollment. Statements that are not historical
facts, such as "anticipates," "estimates," "believes," "hopes,"
"intends," "plans," "expects," "goal," "may," "suggest," "will,"
"potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of risks,
uncertainties and other factors that could cause actual events or
results in future periods to differ materially from what is
expressed in, or implied by, these statements, and include the
expected amount and use of proceeds from the offering and the
expected closing date of the offering. Soligenix cannot assure you
that it will be able to successfully develop, achieve regulatory
approval for or commercialize products based on its technologies,
particularly in light of the significant uncertainty inherent in
developing therapeutics and vaccines against bioterror threats,
conducting preclinical and clinical trials of therapeutics and
vaccines, obtaining regulatory approvals and manufacturing
therapeutics and vaccines, that product development and
commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further funding to
support product development and commercialization efforts,
including grants and awards, maintain its existing grants which are
subject to performance requirements, enter into any biodefense
procurement contracts with the U.S. Government or other countries,
that it will be able to compete with larger and better
financed competitors in the biotechnology industry, that changes in
health care practice, third party reimbursement limitations and
Federal and/or state health care reform initiatives will not
negatively affect its business, or that the U.S. Congress may not
pass any legislation that would provide additional funding for the
Project BioShield program. In addition, there can be no assurance
as to the timing or success of any of its clinical/preclinical
trials. Despite the statistically significant result achieved in
the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of
cutaneous T-cell lymphoma, there can be no assurance that a
marketing authorization from the FDA or EMA will be successful.
Notwithstanding the result in the HyBryte™ (SGX301) Phase 3
clinical trial for the treatment of cutaneous T-cell lymphoma and
the Phase 2a clinical trial of SGX302 for the treatment of
psoriasis, there can be no assurance as to the timing or success of
the clinical trials of SGX302 for the treatment of psoriasis.
Further, there can be no assurance that RiVax® will
qualify for a biodefense Priority Review Voucher (PRV) or that the
prior sales of PRVs will be indicative of any potential sales price
for a PRV for RiVax®. Also, no assurance can be provided
that the Company will receive or continue to receive non-dilutive
government funding from grants and contracts that have been or may
be awarded or for which the Company will apply in the future. These
and other risk factors are described from time to time in filings
with the Securities and Exchange Commission (the "SEC"), including,
but not limited to, the Company's preliminary prospectus
(Registration No. 333-271049) filed with the SEC on May 4, 2023, and Soligenix's reports on Forms
10-Q and 10-K. Unless required by law, Soligenix assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
Soligenix, Inc.
29 Emmons Drive, Suite B-10
Princeton, NJ 08540
View original content to download
multimedia:https://www.prnewswire.com/news-releases/soligenix-inc-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-meeting-301991816.html
SOURCE SOLIGENIX, INC.